Meet Leslie, a 42-year-old mother of three children aged 2, 5, and 7. Leslie's oncologist has just informed her that she has Stage III Ovarian Cancer.
Leslie has a 25% chance of living to see her youngest's 7th birthday.
Women like Leslie represent the challenge and opportunity for the transformation of ovarian cancer treatments.
Many of these women develop multi-drug resistant tumors. This is when cancer cells develop characteristics that
resist multiple drugs due to a number of mutations in the cell that limit the effectiveness
of current ovarian cancer treatment regimens. Finding solutions to this challenge represents a chance to extend the life of
women like Leslie.
Nemucore Medical Innovations Inc is a clinical development company dedicated to the development and
commercialization of life-saving personalized molecularly-targeted therapeutic focused on Women’s
oncology. Nemucore’s molecularly targeted therapeutics have unique design attributes to address multi-drug resistant
and recurrent cancer.
Nemucore is actively developing our portfolio of therapies to bring innovative oncology products to market
and provide patients like Leslie with life-threatening cancers, a new hope.